Cargando…
Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention
The R-carvedilol enantiomer, present in the racemic mixture of the chiral drug carvedilol, does not bind to the β-adrenergic receptors, but exhibits skin cancer preventive activity. For skin delivery, R-carvedilol-loaded transfersomes were prepared using various ratios of drug, lipids, and surfactan...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005314/ https://www.ncbi.nlm.nih.gov/pubmed/36903807 http://dx.doi.org/10.3390/nano13050929 |
_version_ | 1784905049791528960 |
---|---|
author | Shamim, Md Abdullah Shahid, Ayaz Sardar, Pabitra K. Yeung, Steven Reyes, Jeremiah Kim, Jenny Parsa, Cyrus Orlando, Robert Wang, Jeffrey Kelly, Kristen M. Meyskens, Frank L. Andresen, Bradley T. Huang, Ying |
author_facet | Shamim, Md Abdullah Shahid, Ayaz Sardar, Pabitra K. Yeung, Steven Reyes, Jeremiah Kim, Jenny Parsa, Cyrus Orlando, Robert Wang, Jeffrey Kelly, Kristen M. Meyskens, Frank L. Andresen, Bradley T. Huang, Ying |
author_sort | Shamim, Md Abdullah |
collection | PubMed |
description | The R-carvedilol enantiomer, present in the racemic mixture of the chiral drug carvedilol, does not bind to the β-adrenergic receptors, but exhibits skin cancer preventive activity. For skin delivery, R-carvedilol-loaded transfersomes were prepared using various ratios of drug, lipids, and surfactants, and characterized for particle size, zeta potential, encapsulation efficiency, stability, and morphology. Transfersomes were compared for in vitro drug release and ex vivo skin penetration and retention. Skin irritation was evaluated by viability assay on murine epidermal cells and reconstructed human skin culture. Single-dose and repeated-dose dermal toxicity was determined in SKH-1 hairless mice. Efficacy was evaluated in SKH-1 mice exposed to single or multiple ultraviolet (UV) radiations. Transfersomes released the drug at a slower rate, but significantly increased skin drug permeation and retention compared with the free drug. The transfersome with a drug–lipid–surfactant ratio of 1:3:0.5 (T-RCAR-3) demonstrated the highest skin drug retention and was selected for further studies. T-RCAR-3 at 100 µM did not induce skin irritation in vitro and in vivo. Topical treatment with T-RCAR-3 at 10 µM effectively attenuated acute UV-induced skin inflammation and chronic UV-induced skin carcinogenesis. This study demonstrates feasibility of using R-carvedilol transfersome for preventing UV-induced skin inflammation and cancer. |
format | Online Article Text |
id | pubmed-10005314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100053142023-03-11 Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention Shamim, Md Abdullah Shahid, Ayaz Sardar, Pabitra K. Yeung, Steven Reyes, Jeremiah Kim, Jenny Parsa, Cyrus Orlando, Robert Wang, Jeffrey Kelly, Kristen M. Meyskens, Frank L. Andresen, Bradley T. Huang, Ying Nanomaterials (Basel) Article The R-carvedilol enantiomer, present in the racemic mixture of the chiral drug carvedilol, does not bind to the β-adrenergic receptors, but exhibits skin cancer preventive activity. For skin delivery, R-carvedilol-loaded transfersomes were prepared using various ratios of drug, lipids, and surfactants, and characterized for particle size, zeta potential, encapsulation efficiency, stability, and morphology. Transfersomes were compared for in vitro drug release and ex vivo skin penetration and retention. Skin irritation was evaluated by viability assay on murine epidermal cells and reconstructed human skin culture. Single-dose and repeated-dose dermal toxicity was determined in SKH-1 hairless mice. Efficacy was evaluated in SKH-1 mice exposed to single or multiple ultraviolet (UV) radiations. Transfersomes released the drug at a slower rate, but significantly increased skin drug permeation and retention compared with the free drug. The transfersome with a drug–lipid–surfactant ratio of 1:3:0.5 (T-RCAR-3) demonstrated the highest skin drug retention and was selected for further studies. T-RCAR-3 at 100 µM did not induce skin irritation in vitro and in vivo. Topical treatment with T-RCAR-3 at 10 µM effectively attenuated acute UV-induced skin inflammation and chronic UV-induced skin carcinogenesis. This study demonstrates feasibility of using R-carvedilol transfersome for preventing UV-induced skin inflammation and cancer. MDPI 2023-03-03 /pmc/articles/PMC10005314/ /pubmed/36903807 http://dx.doi.org/10.3390/nano13050929 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shamim, Md Abdullah Shahid, Ayaz Sardar, Pabitra K. Yeung, Steven Reyes, Jeremiah Kim, Jenny Parsa, Cyrus Orlando, Robert Wang, Jeffrey Kelly, Kristen M. Meyskens, Frank L. Andresen, Bradley T. Huang, Ying Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title | Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title_full | Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title_fullStr | Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title_full_unstemmed | Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title_short | Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention |
title_sort | transfersome encapsulated with the r-carvedilol enantiomer for skin cancer chemoprevention |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005314/ https://www.ncbi.nlm.nih.gov/pubmed/36903807 http://dx.doi.org/10.3390/nano13050929 |
work_keys_str_mv | AT shamimmdabdullah transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT shahidayaz transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT sardarpabitrak transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT yeungsteven transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT reyesjeremiah transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT kimjenny transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT parsacyrus transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT orlandorobert transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT wangjeffrey transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT kellykristenm transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT meyskensfrankl transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT andresenbradleyt transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention AT huangying transfersomeencapsulatedwiththercarvedilolenantiomerforskincancerchemoprevention |